CPhI "China & World" Medical Forum 2013
CPhI"中国与世界"医药论坛2013 |
主办单位:CPhI Conference 中国医药保健品进出口商会 |
Day One Tuesday June 25th
第一天(6月25日,周二) |
Module A: WHO Prequalification and International Procurement & Purchasing
模块一:WHO预认证与国际招标采购 |
No./序号 | Time/时间 | Topic/主题 | Speaker/演讲人 | Company Name/公司名称 |
B1 | 12:30-13:30 | Registration
登记 | / | / |
13:30-13:40 | Address from Chairman
会长致辞 | Xu Ming,vice president of CCCMHPIE
许铭副会长 | CCCMHPIE
中国医药保健品进出口商会 |
13:40-14:20 | Update on WHO PQ Program
WHO预认证项目最新进展
·WHO PQ globally with focus on medicines and APIs
WHO 全球预认证关注药品和原料药
·WHO PQ approving status with focus on China
WHO 预认证审批现状-重点关注中国
·PQ program update and developing trend
预认证项目最新进展和发展趋势 | Dr Milan Smid, WHO Technical Officer
技术官员,药物政策和标准部负责人 | World Health Organization Prequalification Programme Quality Assurance & Safety of Medicines ,Department of Medicines Policy and Standards (PSM)
WHO预认证与药品质量安全项目 |
14:20-15:00 | Prequalification of APIs and Developing trend
原料药预认证及发展趋势
·Why applying for WHO prequalification of APIs and requirement
为何申请WHO原料药预认证及要求
·Chinese manufacturers started to be successfully involved in API prequalification
中国生产商关注API预认证
·Experience of API prequalification
API预认证经验分享 | Dr Antony Fake, WHO Technical Officer of APIs
技术官员 | World Health Organization Prequalification Programme Quality Assurance & Safety of Medicines
WHO预认证与药品质量安全项目 |
15:00-15:50 | International medicines procurement & purchasing
药品国际招标与采购
·International medicines procurement & purchasing
药品国际招标与采购
·Quality assurance policies of international procurers
国际生产商的质量保证政策
·Experience of manufacturers from participation in PQP
生产商参与PQ认证和国际采购的经验 | Mrs Jacqueline Sawyer, WHO liaison officerSpeaker
WHO国际联络官员 | World Health Organization
WHO |
16:20-16:50 | Panel Discussion
访谈与讨论 | / | / |
Day Two Wednesday June 26th
第二天(6月26日,周三) |
Module B: International Regulatory Environment and Its Effect for Drug Exporting
模块二:国际监管环境对药品出口的影响 |
No./序号 | Time/时间 | Topic/主题 | Speaker/演讲人 | Company Name/公司名称 |
B2 | 8:00-9:00 | Registration
登记 | / | / |
9:00-9:10 | Address from Chairman
大会主席长致辞 | Ms Meng Dongping,vice president
孟冬平副会长 | CCCMHPIE
中国医药保健品进出口商会 |
9:10-9:50 | Pathway to Market Access-European Regulatory Requirements
市场准入途径—进入欧洲市场的法规要求
·Overview of Eu new regulatory requirements
欧盟最新法规概述
·EU moves to control active pharmaceutical ingredients and implementing situation
欧盟转向控制活性原料药及法规实施状况
·Update on GMP in the European Union and effects for third countries
欧盟最新GMP解析及对第三国的影响 | Dr Jerome LEPEINTRE, First Counsellor
欧盟驻华使团第一参赞 | European Union Delegation to China
欧盟驻华使团 |
9:50-9:55 | Questions and Answers
问答 | / | / |
9:55-10:35 | New Development in US Regulatory requirements
美国监管要求新发展
·Regulatory Convergence and International Collaboration
监管趋同与国际合作
·FDA's new guidance and its implication for global regulatory trend
FDA新指南及对全球监管趋势的启示
·Generic drug user fees and effects for DMF and ANDA application from third countries
仿制药付费法案对第三国DMF和简明新药申请的影响 | Dr Wanggang, Assistant Country Director
刚博士,药品官员,副主任 | U.S. FDA China Office
FDA驻华办公室 |
10:35-10:40 | Questions and Answers
问答 | / | / |
10:40-11:20 | Japan Market Regulation and New Rules
日本市场监管和新指令
·New rules for APIs and generics
原料药和仿制药新指令
·Audit and inspect more strictly when joining in PIC/s
加入PIC/s后,审计和现场检查将会更加严格
·MF system and GMP compliance inspection
MF制度和GMP适应性检查 | Masatoshi Morisue, R.Ph.,M.Sc, Director, GMP inspection
森末政利,品质管理部官员 | Japan Pharmaceuticals and Medical Devices Agency
日本药品医疗器械管理局(PMDA) |
11:20-11:25 | Questions and Answers
问答 | / | / |
11:25-12:00 | Update of GMP and GDP in EU and PIC/S
欧盟和PIC/S GMP和GDP指南更新(题目暂定) | Xu Hefeng, Senior Document Manager
徐禾丰,高级文件经理 | Northeast Group.
东北制药集团股份有限公司 |
Module C: New GMP and On-Site Inspection
模块三:新版GMP与现场检查 |
No./序号 | Time/时间 | Topic/主题 | Speaker/演讲人 | Company Name/公司名称 |
B3 | 12:30-13:30 | Registration
报到注册 | / | / |
13:30-13:35 | Address from Chairman
主席致辞 | / | / |
13:35-14:20 | The implementation of new GMP-update in China
中国新版GMP实施与更新动态
·The application status and how many have passed?
中国企业申请和通过状态
·How to issue written confirmation of exported active substances according to EU Directive.
如何根据欧盟指令为出口活性物质出具证明?
·What has been done and what else need to be done before 2015 deadline?
截至2015年,已经做了什么以及还需要做什么
·GMP developing trend and how SFDA encourage getting the new GMP certification?
GMP 发展趋势和SFDA对通过新版GMP的鼓励政策 | / | Officer, SFDA
国家食品药品监督管理总局官员 |
14:20-14:30 | Questions and Answers
问答 | / | / |
14:30-15:20 | on-site inspection requirements and experience from PQP inspections
现场检查要求和PQ认证经验分享
·On-site inspection requirements
现场检查要求
·Better understanding the inspectors' focus to avoid risks in advance
事先了解检验者的关注点来规避风险
·Where the plants can do better? - views and experiences from regulatory officers
在哪些方面工厂可以做的更好:来自管理官员的看法和经验 | Mr Ian Thrussell, senior inspector, WHO
WHO资深检察官 | World Health Organization
WHO |
15:20-15:30 | Questions and Answers
问答 | / | / |
15:30-16:20 | 15:30-16:20
FDA on-site inspection and case sharing
美国FDA现场检查与案例分享
·How to prepare inspection and communicate with inspectors?
如何准备检查和与检查员沟通?
·How to handle deficiencies and apply for changes?
如何处理缺陷和申请变更
·Best practice sharing and case analysis of on-site inspections
现场检查的典范做法分享和案例分析 | Matthew Casale,FDA on-site inspector
现场检查官 | FDA
美国食品和药物管理局 |
16:20-17:00 | Proper reference standards: A topic of utmost relevance during inspections
参考标准:在检查过程中如何选择最适合的标准品 | Dr Christian Zeine, Global Product Manager Pharmaceutical Sector
全球产品负责人 | LGC science Ltd
英国LGC公司 |
17:00-17:10 | Questions and Answers
问答 | / | / |